JPMorgan analyst Jessica Fye lowered the firm’s price target on United Therapeutics (UTHR) to $330 from $350 and keeps an Overweight rating on the shares. The firm sees the upcoming Phase III TETON 2 data for Tyvaso in idiopathic pulmonary fibrosis as a key event for the stock. The readout offers “significantly more upside than downside,” the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UTHR:
- United Therapeutics’ Inhaled Treprostinil Study: A Potential Game-Changer for IPF Treatment
- United Therapeutics’ Promising Study on Inhaled Treprostinil for Pulmonary Fibrosis
- United Therapeutics price target lowered to $385 from $410 at UBS
- Liquidia price target lowered to $40 from $45 at BTIG
- United Therapeutics Shareholders Approve Key Resolutions